INDOMETHACIN | A091276 | GLENMARK PHARMACEUTICALS LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Rising Pharma Holdings, Inc. FDA-2025-P-1164 · 5 docket documents Rising Pharma Holdings, Inc. submitted this suitability petition under section 502(j)(2)(C) of the FDC Act requesting a declaration that an Abbreviated New Drug Application may be submitted for Indomethacin Capsules USP in 18.75 mg and 37.5 mg strengths, which differ from the reference listed drug I | Suitability | 2025-05-09 | Open | Rising Pharma Holdings, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1283
per ea
Lowest NADAC/Unit
$0.0986
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68462030201INDOMETHACIN 50 MG CAPSULE | $0.1283 | EA | Generic | — | 2026-06-17 |
| 68462030205INDOMETHACIN 50 MG CAPSULE | $0.1283 | EA | Generic | — | 2026-06-17 |
| 68462040601INDOMETHACIN 25 MG CAPSULE | $0.0986 | EA | Generic | — | 2026-06-17 |
| 68462040610INDOMETHACIN 25 MG CAPSULE | $0.0986 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.